Stephanie Ann Mulvey, | |
117 Trafalgar Blvd Apt B, Island Park, NY 11558-1722 | |
(646) 596-2906 | |
Not Available |
Full Name | Stephanie Ann Mulvey |
---|---|
Gender | Female |
Speciality | Licensed Vocational Nurse |
Location | 117 Trafalgar Blvd Apt B, Island Park, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1336863703 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164X00000X | Licensed Vocational Nurse | 34342401 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Stephanie Ann Mulvey, 117 Trafalgar Blvd Apt B, Island Park, NY 11558-1722 Ph: (646) 596-2906 | Stephanie Ann Mulvey, 117 Trafalgar Blvd Apt B, Island Park, NY 11558-1722 Ph: (646) 596-2906 |
News Archive
Dental offices now have a better alternative for their in-office music. Custom Channels, a company that creates custom on-line and on-premise radio stations for nationally known brands, has unveiled Smile Radio - a music service specifically designed for dental practices.
A researcher from the University of Houston has found that adults who take prescription opioids for severe pain are more likely to have increased anxiety, depression and substance abuse issues if they also use marijuana.
Tobacco smoke is involved in uncontrolled asthma, a diminished response to anti-asthma drugs, rhinitis, nasal obstruction, and deregulation of the immune system according to an international expert at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.
Angiochem, Inc., a clinical stage biotechnology company, today announced that its second patent has been granted by the U.S. Patent and Trademark office. Patent number 7,902,156, is entitled "Aprotinin Polypeptides for Transporting a Compound Across the Blood-Brain Barrier".
ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it has developed an innovative method for manufacturing the company's lead product candidate, ICT-107, a dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM).
› Verified 2 days ago